|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||75.24 - 76.15|
|52 Week Range||38.47 - 76.27|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||64.75|
We are optimistic about Haemonetics' (HAE) improved Plasma franchise as strong end-market demand for plasma-derived biopharmaceuticals consistently drives growth for the company.
BRAINTREE, Mass. , April 10, 2018 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter fiscal 2018 financial results at 6:00 am EST on Tuesday ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Here we analyze the financials and fundamental factors of Haemonetics (HAE) and Surmodics (SRDX) to decide which is a better investment option.
Haemonetics (HAE) witnesses steady growth in Plasma franchise, led by strong end-market demand for plasma-derived biopharmaceuticals.
Stock Monitor: Alphatec Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 02, 2018 / Active-Investors.com has just released a free research report on Haemonetics Corp. (NYSE: HAE ). If you ...
Embedded Software Adds Key Capability to NexSys PCS Platform BRAINTREE, Mass. , March 28, 2018 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) has received 510(k) clearance from the U.S. Food and Drug ...
Haemonetics (HAE) expects its transfusion management business to grow at a compound annual growth rate (or CAGR) in the low to mid teens. Haemonetics has planned to opt for a key account strategy. The company aims to strengthen its worldwide presence by expanding its global sales team and partnering with other software vendors and players in this segment, like Helmer.
Although Haemonetics expects the overall cell salvage market to grow at a CAGR (compound average growth rate) in the low single digits, the company is focused on significantly improving its existing product line and rapidly increasing its market share in the fastest-growing markets. The above diagram shows the global market shares of Haemonetics and its competitors Fresenius (FMS), Medtronic (MDT), and LivaNova (LIVN) in the cell salvage (or auto transfusion) business in fiscal 2017. Haemonetics has improved on its older Cell Saver product in terms of connectivity and overall programming and has launched the Cell Saver Elite platform.
In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $46.7 million in its hospital business, a YoY (year-over-year) rise of ~9.1%. The hemostasis management franchise within the hospital business reported revenue of close to $19.9 million in fiscal 3Q18, a YoY rise of ~17.6%. The cell processing franchise, which is also part of the hospital business, reported revenue of close to $26.8 million in fiscal 3Q18, a YoY rise of ~3.5%.
Haemonetics (HAE) is focused on initiating the commercial launch of its innovative NexSys PCS device coupled with its embedded firmware, NexLynk DMS, in 2H18. Although the combination of the NexSys PCS device and the NexLynk software is designed to result in a completely integrated and optimal bidirectional system, NexSys PCS supports an open architecture and can work with any other donor management software (or DMS). NexLynk software, however, has been designed to work optimally with NexSys PCS, and it thus eliminates the need for the translation of data between the device and the software.
In fiscal 2017, Haemonetics (HAE) earned almost 46% of its total revenue from its plasma franchise. The company has earned ~48.4% of its total revenue from its plasma franchise YTD (year-to-date) in fiscal 2018. Approximately 91% of the plasma segment’s total revenue in fiscal 2017 was attributable to the sale of disposables.
In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $113.1 million, a YoY (year-over-year) rise of ~4.1%. Haemonetics has earned revenue of nearly $324.4 million from the sale of its products in the plasma franchise YTD (year-to-date) in fiscal 2018, which reflects a YoY rise of ~4.7%. The franchise has reported organic revenue growth of close to 6% YTD in fiscal 2018, and it’s expected to continue witnessing robust growth owing to solid demand for drugs based on human plasma.
On its fiscal 3Q18 earnings conference call, Haemonetics (HAE) increased the guidance for its fiscal 2018 adjusted EPS (earnings per share) by ~$0.12 to the range $1.80–$1.90. Haemonetics has calculated this EPS guidance by assuming a positive impact from its overperformance in fiscal 3Q18 and a negative impact from its anticipated investments in fiscal 4Q18. Excluding the impact of its restructuring and turnaround expenses, the company expects $125 million worth of free cash flow in fiscal 2018.
Haemonetics (HAE) expects to report fiscal 2018 revenue in line with what it witnessed in fiscal 2017. The company also expects to witness 6% YoY revenue growth in its hospital business, lower than its previously projected revenue growth rate range of 7%–10%. Haemonetics, however, expects its blood center business to report a 7% YoY fall in fiscal 2018 revenue, which is at the lower end of its expectation of a fall of 7%–10%.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding HAE is favorable, with net inflows of $4.35 billion.
Here take a quick look on three major MedTech companies that are going to make the best out of the recent Tax-Repeal upheaval.
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.